GC Wellbeing Laennec Shows Pain Relief
GC Wellbeing announced on August 14 that the research results confirming the analgesic effect of Laennec Inj. and the synergistic action observed when co-administered with steroids were published in ‘Scientific Reports’, a sister journal of Nature.This research was jointly conducted by GC Wellbeing
On August 14, GC Wellbeing announced that research confirming the pain-relieving effects of Laennec Inj. and the synergistic action of combining it with steroids had been published in 'Scientific Reports', a journal affiliated with Nature. The study, a collaboration between GC Wellbeing and a team from Yonsei University, examined Laennec Inj.'s mechanisms using an animal model with induced pain.
The findings revealed that Laennec Inj. significantly reduced pain sensitivity, with the analgesic effect increasing in line with the dosage. The study also demonstrated that Laennec Inj. inhibits pain by curbing excessive spinal nerve activity and regulating specific signal transduction pathways.
A key aspect of the research was the effect of combining Laennec Inj. with steroids. When a low-dose steroid was co-administered with Laennec Inj., it produced pain relief equivalent to using a high-dose steroid alone. This finding could potentially reduce the reliance on high-dose steroids in clinical settings. Furthermore, Laennec Inj. effectively combated weight loss, a common side effect of long-term steroid use.
In the control group, subjects treated solely with steroids lost a significant amount of weight, dropping to 88% of their normal weight. However, the group receiving both steroids and Laennec Inj. maintained a normal weight and remained stable.
Jeong Si-young, Head of Research and Development at GC Wellbeing, stated, "This research scientifically validates the pain control mechanism of Laennec and the potential for combining it with steroids." She further added, "It could serve as a new treatment strategy for patients concerned about steroid side effects." Laennec Inj. is a prescription medication originally approved for managing liver function in patients with chronic liver disease, utilizing components derived from human placenta.
Recently, the drug demonstrated successful results in a Phase 3 clinical trial involving high-dose intravenous administration, reinforcing its efficacy in improving liver function. Consequently, the company intends to apply for a change in permission from the Ministry of Food and Drug Safety within the coming year, based on the positive results from the Phase 3 clinical trial.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
